CYH

On the screen CYH looks absurdly cheap: $3.90 for $3.77 of FY2025 diluted EPS, a 1.0x P/E and a $541M market cap against $12.5B of revenue. But the earnings are the trap. Net income swung from -$516M in FY2024 to +$509M in FY2025 (+198.6%) and operating income jumped +174.5% to $1.49B — and the MD&A tells you why: in 2025 the company divested four hospitals, sold a majority stake in three more, and offloaded its ambulatory outreach business to LabCorp, taking in over $1.0B plus $194M in proceeds. The five-year record (net income of $230M, $46M, -$133M, -$516M, +$509M) shows the underlying hospital business runs at roughly breakeven; the 2025 spike is one-time gain-on-sale, not a step-change in operations. Revenue actually fell 1.2% as the hospital base shrank, and that decline continues by design as they sell assets.

The balance sheet is where the real story is. Stockholders' equity is -$1.39B, retained deficit is -$3.57B, and long-term debt is $10.4B against just $260M of cash. Liabilities ($14.0B) exceed assets ($13.2B). This is a distressed capital structure: the enterprise value is dominated by lenders, and the tiny equity slice is effectively a call option on management successfully deleveraging. Operating cash flow of $543M against that debt load leaves little margin for error, and hospital operators face structural pressure from government reimbursement (Medicare/Medicaid), labor costs, and payer mix.